Phase 1 Trial for Potential Alzheimer’s Therapy Yields Positive Results

Phase 1 Trial for Potential Alzheimer’s Therapy Yields Positive Results
A recent Phase 1 clinical study of a potential Alzheimer's therapy showed positive results regarding both safety and biomarkers for cognitive processes. The data support advancing the investigational compound, NDX-1017, developed by Athira Pharma, to later-stage clinical trials. The results, "Phase 1 Study of NDX-1017: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Dementia Patients," were presented recently at the 12th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego, California. Alzheimer's disease is a progressive brain disorder that destroys a person's memory and other thinking skills. Within the brain, neurons exchange information by releasing chemicals called neurotransmitters at synapses, or junctions between neurons. Similar to passing through an area of poor cell coverage, Alzheimer's disease disrupts this process, preventing neurons from communicating with each other. Alzheimer's is currently irreversible and incurable. Although some medications can alleviate symptoms by improving cell-to-cell communication within the brain, none have a prolonged effect. That's why new and improved treatments are constantly sought. The Phase 1 study (
Subscribe or to access all post and page content.